Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation …
F Gao, MS Lin, JS You, MY Zhang, L Cheng… - Cancer Cell …, 2021 - Springer
Background High-dose melphalan (HDMEL, 200 mg/m 2) is considered as the standard
conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT) in …
conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT) in …
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study
M Roussel, V Lauwers-Cances, M Macro… - Blood, The Journal …, 2022 - ashpublications.org
High-dose melphalan (HDM) and transplantation are recommended for eligible patients with
multiple myeloma. No other conditioning regimen has proven to be more effective and/or …
multiple myeloma. No other conditioning regimen has proven to be more effective and/or …
Busulfan, melphalan and carfilzomib high‐dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma
P Hagen, J Norton, S Tsai, L Campo… - British Journal of …, 2024 - Wiley Online Library
The standard of care for fit, newly diagnosed multiple myeloma patients includes induction
therapy followed by consolidative high‐dose chemotherapy with melphalan and autologous …
therapy followed by consolidative high‐dose chemotherapy with melphalan and autologous …
Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features …
M Kim, JJ Lee, CK Min, JY Lee, JC Jo, SS Yoon… - Annals of …, 2023 - Springer
Despite the development of effective agents for multiple myeloma (MM), the management of
patients with high-risk MM (HRMM) is challenging. High-dose treatment followed by …
patients with high-risk MM (HRMM) is challenging. High-dose treatment followed by …